Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04128189 · ClinicalTrials.gov registry record · Phase 3
Shingrix in Renal Transplant Recipients
A Phase 3 study of Kidney Transplant Recipient Response to Shingrix Vaccine, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT04128189 is a Phase 3 study of Kidney Transplant Recipient Response to Shingrix Vaccine that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 132 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04128189, a Phase 3 study of Kidney Transplant Recipient Response to Shingrix Vaccine, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the safety and immune response of the Shingrix vaccine in kidney transplant recipients. Participants on the waiting list for kidney transplant will be given the standard 2 doses of Shingrix. Those participants who have been transplanted by 16 months, may be given a 3rd dose of Shingrix.
Conditions Studied
Interventions
- BIOLOGICAL Shingrix
Study Locations (1)
Colorado
- University of Colorado Anschutz - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2023-03-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04128189
The ClinicalTrials.gov registry entry for NCT04128189 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant Recipient Response to Shingrix Vaccine appearing as the primary indexed condition, and to 1 intervention - of which Shingrix is the first listed.
NCT04128189 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04128189 about?
NCT04128189 is a clinical study titled "Shingrix in Renal Transplant Recipients". This study evaluates the safety and immune response of the Shingrix vaccine in kidney transplant recipients. Participants on the waiting list for kidney transplant will be given the standard 2 doses of Shingrix. Those participants who have been transplanted by 16 months, may be given a 3rd dose of S...
What is the current status of trial NCT04128189?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2023-03-02. Estimated completion is 2026-09.
What conditions does trial NCT04128189 study?
This clinical trial studies the following conditions: Kidney Transplant Recipient Response to Shingrix Vaccine.
What interventions are being tested in trial NCT04128189?
The interventions under investigation include: Shingrix (BIOLOGICAL).
Who is sponsoring clinical trial NCT04128189?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04128189 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.